- Sunesis Pharmaceuticals (SNSS) Q3 results: Revenues: $0.9M (-55.0%); R&D Expense: $6.9M (-1.4%); G&A: $7.2M (+157.1%); Operating Loss: ($13.3M) (-70.5%); Net Loss: ($15.3M) (-101.3%); Loss Per Share: ($0.25) (-56.3%); Quick Assets: $44.7M (+13.7%).
- No guidance given.
Sunesis lowers revenues 55% in Q3
Recommended For You
More Trending News
About VIRX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
VIRX | - | - |
Viracta Therapeutics, Inc. |